Moderna's Cancer Vaccine Poised to Outshine COVID-19 Success

Moderna's COVID-19 vaccine was a groundbreaking success, but its cancer vaccine may be an even bigger win. The company's stock has surged by over 460% in the past year due to outstanding clinical and regulatory progress.

The biotech earned approval for mFLUSIVA, an influenza vaccine that outperformed competing vaccines in phase 3 studies. However, a recent development sent the stock soaring: intismeran autogene, Moderna's investigational personalized cancer vaccine, posted excellent phase 3 clinical trial results.

This is a significant milestone, as no mRNA-based vaccine has ever been approved for cancer treatment. The success of intismeran autogene demonstrates that Moderna's approach can be effective beyond infectious diseases and in oncology. The company is developing the vaccine in collaboration with Merck and is testing it across various cancers.

While sales estimates vary widely, some analysts predict intismeran autogene could generate $16.8 billion in revenue by 2035. This figure could rival Spikevax's lifetime sales of over $50 billion and power consistent revenue growth for Moderna over the next decade.